Brazil health regulator Anvisa on Wednesday allowed resumption of late-stage Brazilian clinical trials for China's Sinovac COVID-19 vaccine, which had been suspended due to a study subject's death that was registered in Sao Paulo as a suicide.
Brazilian medical institute Butantan said in a statement it would restart trials later on Wednesday.
Brazil's president, Jair Bolsonaro, a longtime China critic who has baselessly dismissed the Sinovac vaccine as lacking in credibility, had hailed Monday's suspension as a personal victory.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.